Demographics and baseline disease characteristics of patients with rheumatoid arthritis who received adalimumab at any time during the blinded period or open-label extension of Study DE019 (N = 553). Values are mean (SD) unless otherwise stated.
| Characteristics | Mean (SD) |
|---|---|
| Age, yrs | 55.7 (12.0) |
| Female, % | 74.7 |
| Disease duration, yrs | 10.9 (9.0) |
| Methotrexate use, % | 100 |
| Oral corticosteroid use, % | 50.8 |
| Tender joint count (0–68 joints) | 24.8 (14.4) |
| Swollen joint count (0–66 joints) | 17.7 (10.4) |
| Patient global assessment of pain (0–100 mm VAS)* | 51.4 (23.0) |
| Patient’s global assessment of disease activity (0–100 mm VAS)* | 48.7 (23.1) |
| Physicians global assessment of disease activity (0–100 mm VAS)* | 55.4 (21.2) |
| HAQ DI (0–3 scale)† | 1.4 (0.7) |
| DAS28†† | 5.4 (1.1) |
| C-reactive protein, mg/dl | 1.7 (1.7) |
↵* VAS for pain ranges from 0 = no pain to 100 = severe pain; VAS for disease activity ranges from 0 = no disease activity to 100 = extreme disease activity.
↵† HAQ DI scale ranges from 0 = no difficulty to 3 = unable to perform activity.
↵†† DAS28 is based on a 28-joint assessment for pain or swelling using the C-reactive protein-based formula available from: (www.das-score.nl/index.html). DAS: disease activity score; HAQ DI: Health Assessment Questionnaire Disability Index; VAS: visual analog scale.